SCHEMBL2183971

SCHEMBL2183971

CCc1ccc(/C=C2/C(=O)c3ccccc3C(=O)[C@@H]2C(=O)O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.57
LMNA P02545 9/20 0.57
SMN1; SMN2 Q16637 8/20 0.57
KDM4E B2RXH2 6/20 0.57
HTT P42858 5/20 0.57
RAB9A P51151 5/20 0.57
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
NPC1 O15118 4/20 0.57
TDP1 Q9NUW8 2/20 0.57
ALDH1A1 P00352 6/20 0.47
NPSR1 Q6W5P4 4/20 0.47
HPGD P15428 4/20 0.47
PKM P14618 3/20 0.47
MCL1 Q07820 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
ATM Q13315 2/20 0.47
ALOX12 P18054 1/20 0.47
SLC25A5 P05141 2/20 0.40
EDNRB P24530 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2183977 1.00 MAPT (0.57) MAPTLMNASMN1; SMN2KDM4EHTT
SCHEMBL9403263 0.77 MAPT (0.54) MAPTLMNASMN1; SMN2KDM4EHTT
SCHEMBL30381384 0.73 MAPT (0.63) MAPTLMNASMN1; SMN2KDM4EHTT
SCHEMBL8893921 0.68 MAPT (0.65) MAPTLMNASMN1; SMN2KDM4EHTT
Anthraquinone SCHEMBL28722909 0.66 MAPT (0.67) MAPTLMNASMN1; SMN2KDM4EHTT
SCHEMBL16769905 0.64 ALDH1A1 (0.72) MAPTLMNASMN1; SMN2KDM4EHTT
SCHEMBL15562489 0.64 ALDH1A1 (0.72) MAPTLMNASMN1; SMN2KDM4EHTT
SCHEMBL15562491 0.64 ALDH1A1 (0.72) MAPTLMNASMN1; SMN2KDM4EHTT
SCHEMBL19462864 0.63 ELANE (0.74) MAPTLMNASMN1; SMN2KDM4EHTT
SCHEMBL9840968 0.62 MAPT (0.41) MAPTLMNASMN1; SMN2KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9949980-B2 Drugs to prevent HPV infection WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2018-04-24 US disclosed
US-20150297602-A1 DRUGS TO PREVENT HPV INFECTION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-22 US disclosed
US-9066951-B2 Drugs to treat HPV infection WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2015-06-30 US disclosed
US-20110165220-A1 DRUGS TO PREVENT HPV INFECTION WISCONSIN ALUMNI RESEARCH FOUNDATION 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110165220-A1 DRUGS TO PREVENT HPV INFECTION VHL, PHF13, CDKN1A MAPT 4500/4885LMNA 1743/4885SMN1; SMN2 3894/4885
US-20150297602-A1 DRUGS TO PREVENT HPV INFECTION VHL, PHF13, CDKN1A MAPT 4500/4885LMNA 1743/4885SMN1; SMN2 3894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.